These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30124844)

  • 21. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
    McCallum AD; Pertinez HE; Else LJ; Dilly-Penchala S; Chirambo AP; Sheha I; Chasweka M; Chitani A; Malamba RD; Meghji JZ; Gordon SB; Davies GR; Khoo SH; Sloan DJ; Mwandumba HC
    Clin Infect Dis; 2021 Nov; 73(9):e3365-e3373. PubMed ID: 32856694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
    Mtabho CM; Semvua HH; van den Boogaard J; Irongo CF; Boeree MJ; Colbers A; Burger DM; van Crevel R; van der Ven AJAM; Kibiki GS; Tostmann A; Aarnoutse RE
    J Antimicrob Chemother; 2019 Dec; 74(12):3537-3545. PubMed ID: 31651031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.
    Magis-Escurra C; Later-Nijland HM; Alffenaar JW; Broeders J; Burger DM; van Crevel R; Boeree MJ; Donders AR; van Altena R; van der Werf TS; Aarnoutse RE
    Int J Antimicrob Agents; 2014 Sep; 44(3):229-34. PubMed ID: 24985091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.
    Saktiawati AMI; Harkema M; Setyawan A; Subronto YW; Sumardi ; Stienstra Y; Aarnoutse RE; Magis-Escurra C; Kosterink JGW; van der Werf TS; Alffenaar JC; Sturkenboom MGG
    Clin Pharmacokinet; 2019 Nov; 58(11):1445-1454. PubMed ID: 30997650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
    Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
    BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
    Kumar AKH; Chandrasekaran V; Kannan T; Lavanya J; Swaminathan S; Ramachandran G
    Indian J Med Res; 2018 Mar; 147(3):287-292. PubMed ID: 29923518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites.
    Ramachandran A; Gadgil CJ
    CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1274-1284. PubMed ID: 37431175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
    Gafar F; Wasmann RE; McIlleron HM; Aarnoutse RE; Schaaf HS; Marais BJ; Agarwal D; Antwi S; Bang ND; Bekker A; Bell DJ; Chabala C; Choo L; Davies GR; Day JN; Dayal R; Denti P; Donald PR; Engidawork E; Garcia-Prats AJ; Gibb D; Graham SM; Hesseling AC; Heysell SK; Idris MI; Kabra SK; Kinikar A; Kumar AKH; Kwara A; Lodha R; Magis-Escurra C; Martinez N; Mathew BS; Mave V; Mduma E; Mlotha-Mitole R; Mpagama SG; Mukherjee A; Nataprawira HM; Peloquin CA; Pouplin T; Ramachandran G; Ranjalkar J; Roy V; Ruslami R; Shah I; Singh Y; Sturkenboom MGG; Svensson EM; Swaminathan S; Thatte U; Thee S; Thomas TA; Tikiso T; Touw DJ; Turkova A; Velpandian T; Verhagen LM; Winckler JL; Yang H; Yunivita V; Taxis K; Stevens J; Alffenaar JC;
    Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36328357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
    Chabala C; Turkova A; Hesseling AC; Zimba KM; van der Zalm M; Kapasa M; Palmer M; Chirehwa M; Wiesner L; Wobudeya E; Kinikar A; Mave V; Hissar S; Choo L; LeBeau K; Mulenga V; Aarnoutse R; Gibb D; McIlleron H
    Clin Infect Dis; 2022 May; 74(10):1767-1775. PubMed ID: 34420049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
    Van Aartsen D; Justine M; Mduma E; Mpagama SG; Alshaer MH; Peloquin CA; Mujaga B; Maro A; Gratz J; Kosek M; Liu J; Rogawski McQuade ET; Houpt ER; Thomas TA; Heysell SK
    Lancet Microbe; 2022 Jun; 3(6):e408-e416. PubMed ID: 35659902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
    Alsultan A; Peloquin CA
    Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.